Tucuvi Raises $20M Series A to Scale Autonomous Clinical Voice AI for Healthcare

Tucuvi has secured $20 million in Series A funding to expand its clinical voice AI platform across global healthcare systems. Led by Cathay Innovation and Leadwind, the round includes participation from existing investors to address critical nursing shortages. This capital will support the company as it enters the United States market and continues developing its autonomous care agents.

The Madrid-based startup utilizes a specialized voice agent named LOLA to manage patient interactions through natural phone calls. Unlike standard tools that only record sessions, this platform actively executes clinical workflows such as post-surgical monitoring and chronic disease management. By converting voice conversations into structured medical data, the system allows human care teams to prioritize high-value clinical work.

A major differentiator for Tucuvi is its recent European Class IIb medical device certification. This regulatory milestone makes it the first clinical voice AI validated for high-stakes monitoring and patient triage. The status provides healthcare organizations with the necessary safety guarantees to deploy autonomous AI agents at a massive scale.

The platform has already shown significant impact by automating up to 80% of nursing follow-up tasks for its partners. Patient engagement levels regularly exceed 90% across diverse populations, which is notably higher than traditional app-based solutions. These efficiencies have led to tangible outcomes, such as a 5.5% reduction in hospital readmissions for patients with chronic respiratory issues.

Moving forward, the company intends to transition its technology from isolated automation to end-to-end care management. The team is focusing on building a synthetic workforce that can sustain clinical quality while expanding the capacity of providers. With this new investment, Tucuvi is set to lead the next generation of responsible AI adoption in the healthcare sector.